Lilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 16 ยท Tue 29 Sep 

Imprint

Impressum. Psychedelic Brief is produced in Berlin, so this page carries the details German law requires a publication to state.

Angaben gemäß § 5 TMG

Dhruv Shekhawat
Dauerwaldweg 1
14055 Berlin
Germany

Kontakt

dhruv@psychedelicbrief.com

Verantwortlich für den Inhalt nach § 18 Abs. 2 MStV

Dhruv Shekhawat
Dauerwaldweg 1
14055 Berlin
Germany

In English

Psychedelic Brief is written and published by Dhruv Shekhawat in Berlin. He is responsible for its editorial content. The address and email above are the contact points for any question about what is published here, including a request for correction.

Nature of the content

Intelligence, not advice. Every claim links to its filing. Nothing on this site is medical or legal advice.

Corrections

If something here is wrong, write to the address above and it will be corrected in the open, in the issue rather than quietly. Every call the publication has made is on the ledger, including the ones that have not resolved.